Biotechnology - Asia-Pacific, Amgen

Filter

Current filters:

Asia-PacificAmgen

Popular Filters

Amgen to open China R&D Center at ShanghaiTech

28-09-2013

Amgen and ShanghaiTech University have entered into a memorandum of understanding to form a strategic…

AmgenAsia-PacificBiotechnologyResearch

Amgen and Cytokinetics expand omecamtiv mecarbil accord

12-06-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech company, has expanded its strategic…

AmgenAsia-PacificBiotechnologyCardio-vascularCytokineticsLicensingomecamtiv mecarbil

Amgen and Astellas link up on drugs for unmet medical needs in Japan

29-05-2013

World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

Amgen's Aranesp fails in heart patients; to invest $200 million in Singapore

18-01-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, announced top-line results…

AmgenAranespAsia-PacificBiotechnologyCardio-vascularProductionResearch

Daiichi Sankyo debuts bone cancer drug Ranmark in Japan

17-04-2012

Following National Health Insurance price listing yesterday, Japanese drug major Daiichi Sankyo (TYO:…

AmgenAsia-PacificAstraZenecaBiotechnologyDaiichi SankyodenosumabMarkets & MarketingOncologyPharmaceuticalRanmark

Japanese approval for Regnite and Ranmark

18-01-2012

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based XenoPort (Nasdaq: XNPT) revealed yesterday…

AmgenAsia-PacificAstellas PharmaAstraZenecaBiotechnologyDaiichi SankyodenosumabFinancialNeurologicalOncologyPharmaceuticalRanmarkRegniteRegulationXenoPort

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top